What Makes Alcon (ALC) a Good Investment?
Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here.
Alcon Inc (ALC)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Select Equity Group Robert Joseph Caruso | 6,762,406 | $596,383,041 | +24% | 2.5% |
| 2. | Cantillon Capital Management William Von Mueffling | 2,853,474 | $251,904,684 | +95% | 1.46% |
| 3. | Rudius Management Murat Ozbaydar | 1,982,541 | $175,018,719 | -3% | 37.01% |
| 4. | Antipodes Partners Jacob Mitchell | 1,129,090 | $99,583,046 | -6% | 3.09% |
| 5. | Rokos Capital Management Chris Rokos | 769,778 | $67,956,002 | +383% | 0.3% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,018,994 | $373,573,734 | 1.13% | |
| 2. | 340,728 | $25,352,499 | 0.36% | |
| 3. | 254,844 | $18,986,586 | 0.02% | |
| 4. | 179,400 | $13,353,100 | 0.04% | |
| 5. | 127,904 | $9,530,127 | 0.13% |
News See All
Alcon Inc. (NYSE:ALC) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Alcon Second Quarter 2025 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Stifel Reaffirms Buy on Alcon (ALC), Highlights Eye Care Leader’s Growth Potential
Alcon Inc. (NYSE:ALC) ranks among the best medical stocks to buy according to analysts. On July 10, Stifel reaffirmed its Buy rating for Alcon Inc. (NYSE:ALC) with a $100 price rating.
11 Best Medical Stocks to Buy According to Analysts
As macroeconomic headwinds, regulatory reforms, and geopolitical concerns converge in the second half of 2025, PwC predicts that the health industry's resilience and adaptability will be put to the test...
Should You Continue to Hold Alcon (ALC)?
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here.
Alcon Inc (ALC) Announces Approval of Clareon PanOptix Pro Intraocular Lens
Alcon Inc. (NYSE:ALC) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Alcon Inc.
11 Best 52-Week Low Stocks to Buy Right Now
On July 2, Tom Lee, Fundstrat's Head of Research and CIO, joined CNBC Television to discuss market conditions. He noted that the investors remain skeptical despite strong market gains.
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval
On May 30, BTIG analysts reaffirmed their Buy rating and $99 price target for Alcon Inc. (NYSE:ALC) following the FDA's approval of TRYPTYR for the treatment of dry eye disease (DED).
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease
Alcon Inc. (NYSE:ALC) has announced that the U.S.
Hedge Fund Resource Center Billionaire Hedge Funds
